

Resource Summary Report

Generated by [RRID](#) on Aug 28, 2026

KMS-26

RRID:CVCL_2992

Type: Cell Line

Proper Citation

RRID:CVCL_2992

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2992

Proper Citation: RRID:CVCL_2992

Description: Cell line KMS-26 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Plasma cell myeloma

Defining Citation: [PMID:15215163](#), [PMID:15491288](#), [PMID:17171682](#), [PMID:17692805](#), [PMID:18647998](#), [PMID:18700954](#), [PMID:19306352](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:28196595](#), [PMID:30285677](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:32123307](#)

Comments: Population: Japanese., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: KMS-26

Synonyms: KMS26, Kawasaki Medical School-26

Cross References: BTO:BTO_0006461, EFO:EFO_0006615, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, BioSample:SAMN03472894, BioSample:SAMN10987818, cancercellines:CVCL_2992, Cell_Model_Passport:SIDM01574, CGH-DB:24-1, CGH-DB:9137-4, Cosmic:2081394, Cosmic:2391799, DepMap:ACH-000588, EGA:EGAS00001000610, EGA:EGAS00001002554, GEO:GSM143338, GEO:GSM290298, GEO:GSM887225,

GEO:GSM888299, IARC_TP53:28217, JCRB:JCRB1187, JCRB:NIHS0487, LiGeA:CCLE_629, PharmacDB:KMS26_768_2019, Progenetix:CVCL_2992, Wikidata:Q54900175

ID: CVCL_2992

Record Creation Time: 20220427T220706+0000

Record Last Update: 20260815T234429+0000

Ratings and Alerts

No rating or validation information has been found for KMS-26.

Warning: Discontinued: JCRB; NIHS0487

Population: Japanese., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Tiwari PK, et al. (2026) An orally active dual CBP/p300 degrader targets core dependencies of multiple myeloma. Cell reports, 45(6), 117464.

Ye T, et al. (2024) Identification of WNK1 as a therapeutic target to suppress IgH/MYC expression in multiple myeloma. Cell reports, 43(5), 114211.

Bolomsky A, et al. (2024) IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. Cancer cell, 42(7), 1185.

Shirasaki R, et al. (2021) Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degradors of Oncoproteins. Cell reports, 34(1), 108532.

Vannam R, et al. (2021) Targeted degradation of the enhancer lysine acetyltransferases CBP and p300. Cell chemical biology, 28(4), 503.